Literature DB >> 6243294

Regulatory subunit of the type I cAMP-dependent protein kinase as an inhibitor and substrate of the cGMP-dependent protein kinase.

R L Geahlen, E G Krebs.   

Abstract

The regulatory subunit of the type I cAMP-dependent protein kinase (Rt) serves as a substrate for the phosphotransferase reaction catalyzed by cGMP-dependent protein kinase (Km = 2.2 microM). The reaction is stimulated by cGMP when RI . cAMP is the substrate, but not when nucleotide-free RI is used. The cGMP-dependent protein kinase catalyzes the incorporation of 2 mol of phosphate/mol of RI dimer in the presence of cAMP and a self-phosphorylation reaction to the extent of 4 mol of phosphate/mol of enzyme dimer. In the absence of cAMP, RI is a competitive inhibitor of the phosphorylation of histone H2B (Ki = 0.25 microM) and of the synthetic peptide substrate Leu-Arg-Arg-Ala-Ser-Leu-Gly (Ki = 0.15 microM) by the cGMP-dependent enzyme. Nucleotide-free RI also inhibits the intramolecular self-phosphorylation of cGMP-dependent protein kinase. The inhibition of the phosphorylation reactions are reversed by cAMP. The catalytic subunit of cAMP-dependent protein kinase does not catalyze the phosphorylation of RIand does not significantly alter the ability of RI to serve as a substrate or an inhibitor of cGMP-dependent protein kinase. These observations are consistent with the concept that the cGMP- and cAMP-dependent protein kinases are closely related proteins whose functional domains may interact.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243294

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus.

Authors:  Y F Lu; E R Kandel; R D Hawkins
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Differential responses of cyclic GMP-dependent and cyclic AMP-dependent protein kinases to synthetic peptide inhibitors.

Authors:  D B Glass
Journal:  Biochem J       Date:  1983-07-01       Impact factor: 3.857

4.  Primary structure of the regulatory subunit of type II cAMP-dependent protein kinase from bovine cardiac muscle.

Authors:  K Takio; S B Smith; E G Krebs; K A Walsh; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

5.  Reconstitution of rods from tobacco mosaic virus protein and RNA modified with bulky carcinogens.

Authors:  H Fraenkel-Conrat; B Singer; Y Takanami; R M Santella; D Grunberger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

Review 6.  Exploring the Plasmodium falciparum cyclic-adenosine monophosphate (cAMP)-dependent protein kinase (PfPKA) as a therapeutic target.

Authors:  Nina M Haste; Hana Talabani; Alex Doo; Anais Merckx; Gordon Langsley; Susan S Taylor
Journal:  Microbes Infect       Date:  2012-05-22       Impact factor: 2.700

7.  Dibutyryl cAMP treatment of neuroblastoma-glioma hybrid cells results in selective increase in cAMP-receptor protein (R-I) as measured by monospecific antibodies.

Authors:  S M Lohmann; G Schwoch; G Reiser; R Port; U Walter
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

8.  The central role of cAMP in regulating Plasmodium falciparum merozoite invasion of human erythrocytes.

Authors:  Amrita Dawn; Shailja Singh; Kunal R More; Faiza Amber Siddiqui; Niseema Pachikara; Ghania Ramdani; Gordon Langsley; Chetan E Chitnis
Journal:  PLoS Pathog       Date:  2014-12-18       Impact factor: 6.823

9.  Sites of phosphorylation and mutation in regulatory subunit of cyclic AMP-dependent protein kinase from S49 mouse lymphoma cells: mapping to structural domains.

Authors:  R A Steinberg
Journal:  J Cell Biol       Date:  1983-10       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.